China May HSBC flash PMI Hits 7-Month Low on Weak Demand
Abbott Laboratories
featured
Cramer has been looking at long-term losers to see if any show potential. He’s found something.
» Read More
More
-
A few companies are signaling positive factors for stocks, TheStreet CIO Stephanie Link says.
-
In the U.S. volumes at hospitals, in-patient and out-patient are soft, "said David Heupel, senior healthcare analyst at Thrivent Investment Management.
-
General Electric Co cuts its estimate for profit growth in its core industrial units, citing weakness in Europe and sliding wind turbine sales, unnerving Wall Street and pushing its stock down in morning trading. (GENERALELECTRIC-RESULTS/, moving shortly, by Ernest Scheyder, 1,000 words). McDonald's sees no restaurant rebound in April.
-
MOSCOW, April 19- Russia's government commission on foreign investment has turned down U.S. group Abbott Laboratories' request to buy Russian vaccine maker Petrovax, the head of Russia's competition regulator said on Friday.
-
April 17- Abbott Laboratories on Wednesday reported higher quarterly earnings after splitting off its branded drug business, and the company said demand was strong for its infant formulas and diagnostic products.
-
U.S. stock index futures were lower Wednesday, pressured by some weaker-than-expected earnings and amid worries over global growth.
-
April 17- Abbott Laboratories reported higher earnings from continuing operations, as demand for its nutritional and diagnostic products offset declining sales of the company's medical devices.
-
April 17- Abbott Laboratories' quarterly earnings from continuing operations were roughly in line with Wall Street forecasts, rising sharply on demand for the company's nutritional and diagnostic products.
-
Earnings season kicks into high gear in the week ahead. Plus, at least 10 Fed speeches. How risk-averse are investors? Oh, this is going to put them to the test. Rest up.
-
WASHINGTON, April 4- Cordis Corp, a Johnson and Johnson subsidiary, did not infringe on a patent owned by a radiologist in making its Cypher stents, an appeals court said on Thursday, reversing a ruling by a lower court that ordered Cordis to pay $482 million.
-
U.S. stock index futures shaved their gains to turn narrowly mixed Wednesday after a report showed private employers added less jobs than expected in March.
-
At least three of the world's top drugmakers are bidding for Brazil's Ache Laboratorios Farmaceuticos in an auction that may value the group at more than $5 billion, people familiar with the matter said.
-
Stung by a landmark patent defeat, Western drugmakers will be wary about launching new products in India, but they cannot afford to quit a country with a market potential as large as India's.
-
Aggregate dividends per share for S&P 500 companies grew nearly 16 percent year-over-year at the end of last year, and the number of companies paying a dividend over the trailing month period hit a new, 13-year high, according to Factset.
-
LONDON/ MUMBAI, April 2- Stung by a landmark patent defeat, Western drugmakers will be wary about launching new products in India, but they cannot afford to quit a country tipped to be the world's eighth largest market for medicines by 2016..
-
The "Fast Money" traders share their final trades of the day and what traders are looking out for on Friday.
-
March 10- A drug-coated heart stent from Japan's Terumo Corp with a dissolving polymer proved just as effective as Abbott Laboratories' top-selling Xience stent at preventing a second procedure to clear the artery, a large study found.
-
The pharmaceutical and biopharmaceutical sectors have been marching steadily higher. TheStreet.com reports on two stocks with potential to appreciate.
-
Feb 21- Abbott Laboratories said on Thursday it was working with Johnson& Johnson to see if a genetic diagnostic test made by Abbott would help to identify patients most likely to benefit from a promising experimental leukemia treatment.
